Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017095725) ARYL SULFONAMIDES AS BLT1 ANTAGONISTS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/095725 International Application No.: PCT/US2016/063810
Publication Date: 08.06.2017 International Filing Date: 28.11.2016
IPC:
C07D 413/04 (2006.01) ,A61K 31/35 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
35
having six-membered rings with one oxygen as the only ring hetero atom
Applicants:
MERCK SHARP & DOHME CORP. [US/US]; 126 East Lincoln Avenue Rahway, New Jersey 07065-0907, US
HAN, Yongxin [CA/US]; US (US)
SILIPHAIVANH, Phieng [US/US]; US (US)
SPENCER, Kerrie [US/US]; US (US)
TUMMANAPALLI, Satyanarayana [IN/US]; US (US)
Inventors:
HAN, Yongxin; US
SILIPHAIVANH, Phieng; US
SPENCER, Kerrie; US
TUMMANAPALLI, Satyanarayana; US
Common
Representative:
MERCK SHARP & DOHME CORP.; 126 East Lincoln Avenue Rahway, New Jersey 07065-0907, US
Priority Data:
62/260,91330.11.2015US
Title (EN) ARYL SULFONAMIDES AS BLT1 ANTAGONISTS
(FR) SULFONAMIDES D'ARYLE UTILISÉS EN TANT QU'ANTAGONISTES DE BLT1
Abstract:
(EN) Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene B4 receptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene B4 receptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Non-alcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer.
(FR) La présente invention concerne de nouveaux composés de formule structurale (I), et leurs sels pharmaceutiquement acceptables, qui sont des antagonistes du récepteur 1 de leucotriène B4 (BLT1) et peuvent être utiles dans le traitement, la prévention et la suppression de maladies médiées par le récepteur 1 de leucotriène B4 (BLT1). Les composés selon la présente invention peuvent être utiles pour traiter le diabète de type 2, l'insulinorésistance, l'hyperglycémie, la dyslipidémie, les troubles lipidiques, l'obésité, l'hypertension, la stéatose hépatique non alcoolique/la stéatohépatite non alcoolique, le syndrome métabolique, l'athérosclérose et le cancer.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP3383869US20180312499